(Total Views: 189)
Posted On: 01/05/2024 7:58:51 AM
Post# of 79
EYEPOINT PHARMACEUTICALS: A BOON FOR EYE DISEASE PATIENTS
$EYPT
Excited to share an article about EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) - the Company develops and commercializes therapeutics to improve the lives of patients with severe eye disorders.
EyePoint is known for its proprietary Durasert drug delivery platform, which has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products. The Company is developing solutions to treat diseases of the retina, such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR), which has an estimated market size of $12.27 billion by 2032.
EyePoint's pipeline includes products such as EYP -1901 and EYP-201 - these represent multi-billion dollar opportunities, making the Company an exciting watch.
Read on to know more:
https://www.aviseanalytics.com/eyepoint-pharm...-patients/
$EYPT
Excited to share an article about EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) - the Company develops and commercializes therapeutics to improve the lives of patients with severe eye disorders.
EyePoint is known for its proprietary Durasert drug delivery platform, which has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products. The Company is developing solutions to treat diseases of the retina, such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR), which has an estimated market size of $12.27 billion by 2032.
EyePoint's pipeline includes products such as EYP -1901 and EYP-201 - these represent multi-billion dollar opportunities, making the Company an exciting watch.
Read on to know more:
https://www.aviseanalytics.com/eyepoint-pharm...-patients/
(0)
(0)
